A co-drug according to Formula (I) or Formula (II) is provided,R—;X—;NH—;CO—;CO—;OR1 ; ;(I)R—;X—;CO—;O—;CH2—;CO—;OR1 ; ;(II)wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—;OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.